Wu Jie, Zheng Ying, Zhang Li-Na, Gu Cai-Li, Chen Wang-Li, Chang Min-Qiang
Department of Respiratory and Oncology, 72 Group Army Hospital of PLA, Huzhou 313000, Zhejiang Province, China.
Department of Otorhinolaryngology, 72 Group Army Hospital of PLA, Huzhou 313000, Zhejiang Province, China.
World J Clin Cases. 2024 Jun 6;12(16):2704-2712. doi: 10.12998/wjcc.v12.i16.2704.
Immunotherapy and associated immune regulation strategies gained huge attraction in order to be utilized for treatment and prevention of respiratory diseases. Engineering specifically nanomedicines can be used to regulate host immunity in lungs in the case of respiratory diseases including coronavirus disease 2019 (COVID-19) infection. COVID-19 causes pulmonary embolisms, thus new therapeutic options are required to target thrombosis, as conventional treatment options are either not effective due to the complexity of the immune-thrombosis pathophysiology. In this review, we discuss regulation of immune response in respiratory diseases especially COVID-19. We further discuss thrombosis and provide an overview of some antithrombotic nanoparticles, which can be used to develop nanomedicine against thrombo-inflammation induced by COVID-19 and other respiratory infectious diseases. We also elaborate the importance of immunomodulatory nanomedicines that can block pro-inflammatory signalling pathways, and thus can be recommended to treat respiratory infectious diseases.
免疫疗法及相关免疫调节策略因其可用于治疗和预防呼吸道疾病而备受关注。在包括2019冠状病毒病（COVID-19）感染在内的呼吸道疾病中，工程化纳米药物，特别是纳米医学，可用于调节肺部的宿主免疫力。COVID-19会导致肺栓塞，因此需要新的治疗方案来针对血栓形成，因为传统治疗方案由于免疫血栓形成病理生理学的复杂性而无效。在这篇综述中，我们讨论了呼吸道疾病尤其是COVID-19中免疫反应的调节。我们还讨论了血栓形成，并概述了一些抗血栓纳米颗粒，这些纳米颗粒可用于开发针对COVID-19和其他呼吸道传染病引起的血栓炎症的纳米药物。我们还阐述了可阻断促炎信号通路的免疫调节纳米药物的重要性，因此可推荐其用于治疗呼吸道传染病。
